SLRN earnings call for the period ending September 30, 2023.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate.
What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...
A competitor's clinical trial stumble may be benefiting MoonLake.